Randomised controlled trial of continued intravenous versus switching to subcutaneous infliximab in inflammatory bowel disease: the Subcutaneous Infliximab Switch Study (SISS). - Chetwood, J.; Redmond, D.; Kermeen, M.; Kariyawasam, V.; Thin, L.; Lightowler, D.; Corte, C.; Ding, N. J. S.; Ward, M. G.; Little, R.; Kwan, V.; De Cruz, P.; et al. (Journal of Crohn's & Colitis, 2026)